Charles River Laboratories International (CRL) Gains from Investment Securities (2021 - 2023)

Charles River Laboratories International has reported Gains from Investment Securities for 3 years, with the latest figure at $1.8 million in Q3 2023.

• On a quarterly basis, Gains from Investment Securities rose 115.12% year-over-year to $1.8 million in Q3 2023; TTM through Dec 2023 was $1.8 million, a 148.23% increase from a year earlier, with the FY2023 full-year figure at $1.8 million, up 148.23% from the prior year.
• Gains from Investment Securities was $1.8 million for Q3 2023 at Charles River Laboratories International, down from $11.7 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $11.7 million in Q4 2022, with the low at -$23.9 million in Q4 2021.
• Average Gains from Investment Securities over 3 years is -$6.0 million, with a median of -$6.9 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities surged 148.73% in 2022, then surged 115.12% in 2023.
• Over 3 years, Gains from Investment Securities stood at -$23.9 million in 2021, then soared by 148.73% to $11.7 million in 2022, then sank by 84.49% to $1.8 million in 2023.
• The last three Gains from Investment Securities figures came in at $1.8 million (Q3 2023), $11.7 million (Q4 2022), and -$12.0 million (Q2 2022), per Business Quant data.